"...MYRX is presenting the most challenging Azixa data..."
In some ways, it isn't the most challenging. It's hard to get ethics committee approval to collect, for sure. Basically, the enrollees have a life expectancy of under two months and a prospect of perhaps 5 decent days in that period to say goodbye and finish winding up their affairs. The time they'll devote to the study is very precious, but with such a poor prognosis, any effect at all will show like a beacon.
Thanks for the clinical clarity, jacosa. I suppose their loss from the trials makes that data available for review before the trial officially ends (with ethics committee sanction), i.e. the SNO poster.